Sec. 51.0003.  REQUIREMENTS; NOTICE.  (a)  The program:
(1)  must collaborate with physicians and health care providers to notify a prospective subject about the program when:
(A)  the prospective subject provides informed consent for a cancer clinical trial; or
(B)  funding is available to provide the program for the cancer clinical trial in which the prospective subject participates;
(2)  must reimburse subjects based on financial need, which may include reimbursement to subjects whose income is at or below 700 percent of the federal poverty level;
(3)  must provide reimbursement for ancillary costs, including costs described by Section 51.0002, to eliminate the financial barriers to enrollment in a clinical trial;
(4)  may provide reimbursement for reasonable ancillary costs, including costs described by Section 51.0002, to one family member, friend, or other person who attends a cancer clinical trial to support a subject; and
(5)  must comply with applicable federal and state laws.
(b)  The independent, third-party organization administering the program shall provide written notice to prospective subjects of the requirements described by Subsection (a).
Added by Acts 2019, 86th Leg., R.S., Ch. 1157 (H.B. 3147), Sec. 2, eff. September 1, 2019.
Redesignated by Acts 2021, 87th Leg., R.S., Ch. 915 (H.B. 3607), Sec. 21.001(53), eff. September 1, 2021.
Amended by: 
Acts 2021, 87th Leg., R.S., Ch. 915 (H.B. 3607), Sec. 21.002(9), eff. September 1, 2021.